Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

eIF2B activator prevents neurological defects caused by a chronic integrated stress response.

Wong YL, LeBon L, Basso AM, Kohlhaas KL, Nikkel AL, Robb HM, Donnelly-Roberts DL, Prakash J, Swensen AM, Rubinstein ND, Krishnan S, McAllister FE, Haste NV, O'Brien JJ, Roy M, Ireland A, Frost JM, Shi L, Riedmaier S, Martin K, Dart MJ, Sidrauski C.

Elife. 2019 Jan 9;8. pii: e42940. doi: 10.7554/eLife.42940.

2.

Short-term oral gavage administration of adenine induces a model of fibrotic kidney disease in rats.

Zhu CZ, Doyle KJ, Nikkel AL, Olsen L, Namovic MT, Salte K, Widomski D, Su Z, Donnelly-Roberts DL, Gopalakrishnan MM, McGaraughty S.

J Pharmacol Toxicol Methods. 2018 Nov - Dec;94(Pt 1):34-43. doi: 10.1016/j.vascn.2018.04.003. Epub 2018 Apr 22.

PMID:
29684554
3.

Synthesis and in vitro activity of N-benzyl-1-(2,3-dichlorophenyl)-1H-tetrazol-5-amine P2X(7) antagonists.

Perez-Medrano A, Donnelly-Roberts DL, Florjancic AS, Nelson DW, Li T, Namovic MT, Peddi S, Faltynek CR, Jarvis MF, Carroll WA.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3297-300. doi: 10.1016/j.bmcl.2011.04.024. Epub 2011 Apr 14.

PMID:
21536435
4.

Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.

Vortherms TA, Swensen AM, Niforatos W, Limberis JT, Neelands TR, Janis RS, Thimmapaya R, Donnelly-Roberts DL, Namovic MT, Zhang D, Brent Putman C, Martin RL, Surowy CS, Jarvis MF, Scott VE.

Inflamm Res. 2011 Jul;60(7):683-93. doi: 10.1007/s00011-011-0322-9. Epub 2011 Mar 11.

PMID:
21394563
5.

Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors.

Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF.

Br J Pharmacol. 2009 Aug;157(7):1203-14. doi: 10.1111/j.1476-5381.2009.00233.x. Epub 2009 Jun 22.

6.

Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain.

Perez-Medrano A, Donnelly-Roberts DL, Honore P, Hsieh GC, Namovic MT, Peddi S, Shuai Q, Wang Y, Faltynek CR, Jarvis MF, Carroll WA.

J Med Chem. 2009 May 28;52(10):3366-76. doi: 10.1021/jm8015848.

PMID:
19397270
7.

[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.

Donnelly-Roberts DL, Namovic MT, Surber B, Vaidyanathan SX, Perez-Medrano A, Wang Y, Carroll WA, Jarvis MF.

Neuropharmacology. 2009 Jan;56(1):223-9. doi: 10.1016/j.neuropharm.2008.06.012. Epub 2008 Jun 17.

PMID:
18602931
8.

Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists.

Nelson DW, Sarris K, Kalvin DM, Namovic MT, Grayson G, Donnelly-Roberts DL, Harris R, Honore P, Jarvis MF, Faltynek CR, Carroll WA.

J Med Chem. 2008 May 22;51(10):3030-4. doi: 10.1021/jm701516f. Epub 2008 Apr 26.

PMID:
18438986
9.

Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists.

Florjancic AS, Peddi S, Perez-Medrano A, Li B, Namovic MT, Grayson G, Donnelly-Roberts DL, Jarvis MF, Carroll WA.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2089-92. doi: 10.1016/j.bmcl.2008.01.095. Epub 2008 Jan 30.

PMID:
18272366
10.

Synthesis and in vitro activity of N'-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonists.

Morytko MJ, Betschmann P, Woller K, Ericsson A, Chen H, Donnelly-Roberts DL, Namovic MT, Jarvis MF, Carroll WA, Rafferty P.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2093-6. doi: 10.1016/j.bmcl.2008.01.094. Epub 2008 Jan 30.

PMID:
18272365
11.

Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists.

Carroll WA, Kalvin DM, Perez Medrano A, Florjancic AS, Wang Y, Donnelly-Roberts DL, Namovic MT, Grayson G, Honoré P, Jarvis MF.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):4044-8. Epub 2007 Apr 27.

PMID:
17482819
12.

P2X7-related modulation of pathological nociception in rats.

McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, Harris RR, Zhang XF, Shieh CC, Wismer CT, Zhu CZ, Gauvin DM, Fabiyi AC, Honore P, Gregg RJ, Kort ME, Nelson DW, Carroll WA, Marsh K, Faltynek CR, Jarvis MF.

Neuroscience. 2007 Jun 8;146(4):1817-28. Epub 2007 May 3.

PMID:
17478048
13.
14.

Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.

Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, Nelson SL, Cowart MD, Nakane M, Miller LN, Uchic ME, Terranova MA, El-Kouhen OF, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Chang R, Martino BR, Wetter JM, Marsh KC, Martin R, Darbyshire JF, Gintant G, Hsieh GC, Moreland RB, Sullivan JP, Brioni JD, Stewart AO.

J Med Chem. 2006 Dec 14;49(25):7450-65.

PMID:
17149874
15.

A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor.

Rueter LE, Donnelly-Roberts DL, Curzon P, Briggs CA, Anderson DJ, Bitner RS.

CNS Drug Rev. 2006 Summer;12(2):100-12. Review.

16.

1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.

Kolasa T, Matulenko MA, Hakeem AA, Patel MV, Mortell K, Bhatia P, Henry R, Nakane M, Hsieh GC, Terranova MA, Uchic ME, Miller LN, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino B, El Kouhen O, Marsh KC, Wetter JM, Moreland RB, Brioni JD, Stewart AO.

J Med Chem. 2006 Aug 24;49(17):5093-109.

PMID:
16913699
17.

Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.

Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, Grayson G, Namovic MT, Donnelly-Roberts DL, Niforatos W, Honore P, Jarvis MF, Faltynek CR, Carroll WA.

J Med Chem. 2006 Jun 15;49(12):3659-66.

PMID:
16759108
18.

2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.

Nakane M, Cowart MD, Hsieh GC, Miller L, Uchic ME, Chang R, Terranova MA, Donnelly-Roberts DL, Namovic MT, Miller TR, Wetter JM, Marsh K, Stewart AO, Brioni JD, Moreland RB.

Neuropharmacology. 2005 Jul;49(1):112-21. Epub 2005 Apr 1.

PMID:
15992586
19.

Pharmacological characterization of P2X7 receptors in rat peritoneal cells.

Chen YW, Donnelly-Roberts DL, Namovic MT, Gintant GA, Cox BF, Jarvis MF, Harris RR.

Inflamm Res. 2005 Mar;54(3):119-26.

PMID:
15883745
20.

In vitro and in vivo effects of an alpha3 neuronal nicotinic acetylcholine receptor antisense oligonucleotide.

Adams MR, Nikkel AL, Donnelly-Roberts DL, Watt AT, Johnston JF, Cowsert LM, Butler M, Kroeger PE, Frost L, Curzon P, Decker MW, Bitner RS.

Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):67-79.

PMID:
15469883
21.

Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligand.

Matulenko MA, Surber B, Fan L, Kolasa T, Nakane M, Terranova MA, Uchic ME, Miller LN, Chang R, Donnelly-Roberts DL, Namovic MT, Moreland RB, Brioni JD, Stewart AO.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5095-8.

PMID:
15380206
22.

Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).

Moreland RB, Nakane M, Donnelly-Roberts DL, Miller LN, Chang R, Uchic ME, Terranova MA, Gubbins EJ, Helfrich RJ, Namovic MT, El-Kouhen OF, Masters JN, Brioni JD.

Biochem Pharmacol. 2004 Aug 15;68(4):761-72.

PMID:
15276084
23.

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.

Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ 3rd, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO.

J Med Chem. 2004 Jul 15;47(15):3853-64.

PMID:
15239663
24.

Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3-methylphenyl)acetamides: selective dopamine D4 receptor agonists.

Matulenko MA, Hakeem AA, Kolasa T, Nakane M, Terranova MA, Uchic ME, Miller LN, Chang R, Donnelly-Roberts DL, Namovic MT, Moreland RB, Brioni JD, Stewart AO.

Bioorg Med Chem. 2004 Jul 1;12(13):3471-83.

PMID:
15186832
25.

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.

Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, Lin NH, Osinski MA, Reinhart GA, Buckley MJ, Martin RL, McDermott JS, Preusser LC, Seifert TR, Su Z, Cox BF, Decker MW, Sullivan JP.

CNS Drug Rev. 2004 Summer;10(2):167-82. Review.

26.

Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

Brioni JD, Moreland RB, Cowart M, Hsieh GC, Stewart AO, Hedlund P, Donnelly-Roberts DL, Nakane M, Lynch JJ 3rd, Kolasa T, Polakowski JS, Osinski MA, Marsh K, Andersson KE, Sullivan JP.

Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6758-63. Epub 2004 Apr 15.

27.

Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.

Stewart AO, Cowart MD, Moreland RB, Latshaw SP, Matulenko MA, Bhatia PA, Wang X, Daanen JF, Nelson SL, Terranova MA, Namovic MT, Donnelly-Roberts DL, Miller LN, Nakane M, Sullivan JP, Brioni JD.

J Med Chem. 2004 Apr 22;47(9):2348-55.

PMID:
15084133
28.

Mitogen-activated protein kinase and caspase signaling pathways are required for P2X7 receptor (P2X7R)-induced pore formation in human THP-1 cells.

Donnelly-Roberts DL, Namovic MT, Faltynek CR, Jarvis MF.

J Pharmacol Exp Ther. 2004 Mar;308(3):1053-61. Epub 2003 Nov 21.

PMID:
14634045
29.

Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine.

Hsieh GC, Hollingsworth PR, Martino B, Chang R, Terranova MA, O'Neill AB, Lynch JJ, Moreland RB, Donnelly-Roberts DL, Kolasa T, Mikusa JP, McVey JM, Marsh KC, Sullivan JP, Brioni JD.

J Pharmacol Exp Ther. 2004 Jan;308(1):330-8. Epub 2003 Oct 20.

PMID:
14569075
30.

Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat.

Bitner RS, Nikkel AL, Curzon P, Donnelly-Roberts DL, Puttfarcken PS, Namovic M, Jacobs IC, Meyer MD, Decker MW.

Brain Res. 2000 Jul 14;871(1):66-74.

PMID:
10882784
31.

Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.

Holladay MW, Bai H, Li Y, Lin NH, Daanen JF, Ryther KB, Wasicak JT, Kincaid JF, He Y, Hettinger AM, Huang P, Anderson DJ, Bannon AW, Buckley MJ, Campbell JE, Donnelly-Roberts DL, Gunther KL, Kim DJ, Kuntzweiler TA, Sullivan JP, Decker MW, Arneric SP.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2797-802.

PMID:
9873625
32.

Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist.

Lin NH, Gunn DE, Li Y, He Y, Bai H, Ryther KB, Kuntzweiler T, Donnelly-Roberts DL, Anderson DJ, Campbell JE, Sullivan JP, Arneric SP, Holladay MW.

Bioorg Med Chem Lett. 1998 Feb 3;8(3):249-54.

PMID:
9871663
33.

The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594.

Decker MW, Curzon P, Holladay MW, Nikkel AL, Bitner RS, Bannon AW, Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Williams M, Arneric SP.

J Physiol Paris. 1998 Jun-Aug;92(3-4):221-4. Review.

PMID:
9789812
34.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.

Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP.

J Pharmacol Exp Ther. 1998 May;285(2):777-86.

PMID:
9580626
35.

Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.

Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJ, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP.

J Med Chem. 1998 Feb 12;41(4):407-12.

PMID:
9484491
36.
37.

Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.

Lin NH, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts DL, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Buccafusco JJ, Prendergast MA, Sullivan JP, Williams M, Arneric SP, Holladay MW.

J Med Chem. 1997 Jan 31;40(3):385-90.

PMID:
9022806
38.

In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418.

Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP.

Brain Res. 1996 May 6;719(1-2):36-44.

PMID:
8782861
39.

Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.

Abreo MA, Lin NH, Garvey DS, Gunn DE, Hettinger AM, Wasicak JT, Pavlik PA, Martin YC, Donnelly-roberts DL, Anderson DJ, Sullivan JP, Williams M, Arneric SP, Holladay MW.

J Med Chem. 1996 Feb 16;39(4):817-25.

PMID:
8632405
40.

Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists.

Donnelly-Roberts DL, Arneric SP, Sullivan JP.

Biochem Biophys Res Commun. 1995 Aug 15;213(2):657-62.

PMID:
7544126
41.

Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors.

Decker MW, Anderson DJ, Brioni JD, Donnelly-Roberts DL, Kang CH, O'Neill AB, Piattoni-Kaplan M, Swanson S, Sullivan JP.

Eur J Pharmacol. 1995 Jun 23;280(1):79-89.

PMID:
7498257
42.
43.
45.
48.

Antibodies against an alpha-bungarotoxin-binding peptide of the alpha-subunit of the acetylcholine receptor.

Donnelly-Roberts DL, Lentz TL.

Biochem Biophys Res Commun. 1989 Apr 14;160(1):289-95.

PMID:
2469418

Supplemental Content

Loading ...
Support Center